Figure 6.

Ubiquitination of Bcl-B affects its potential to inhibit cell death. J16 (left panels) and MOLT-4 (right panels) cell lines expressing empty vector (EV), WT Bcl-B or K/R mutant Bcl-B (Figure 3a) were treated with the targeted anti-cancer drugs ABT-737, roscovitine or TRAIL, or the conventional anti-cancer drugs etoposide or vincristine, at the indicated dose range. After 24 h, dead cells were identified by flow cytometric analysis of propidium iodide uptake. Data represent mean +s.d. from three independent experiments. Asterisks indicate statistically significant difference (Student's t-test; *P<0.05, **P<0.01, ***P<0.001).